1. Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals announces positive results in first phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C) [media release]. 2016. http://www.businesswire.com/news/home/20161209005270/en/Synergy-Pharmaceuticals-Announces-Positive-Results-Phase-3 . Accessed 24 Feb 2017.
2. Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013;58(9):2580–6.
3. US FDA. Trulance (plecanatide) tablets: US prescribing information. 2017. http://content.stockpr.com/synergypharma/files/pages/synergypharma/db/147/description/03+Plecanatide+label_clean_2017-01-19.pdf . Accessed 24 Feb 2017.
4. Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals announces closing of merger with Callisto Pharmaceuticals [media release]. 2013. http://ir.synergypharma.com/press-releases/detail/1203/synergy-pharmaceuticals-announces-closing-of-merger-with . Accessed 24 Feb 2017.
5. EpiStem Ltd. Callisto Pharmaceuticals selects EpiStem to provide specialised preclinical efficacy testing for guanilib, its lead drug candidate for IBD [media release]. 2006. http://www.prnewswire.com/news-releases/callisto-pharmaceuticals-selects-epistem-to-provide-specialised-preclinical-efficacy-testing-for-guanilib-its-lead-drug-candidate-for-ibd-69973687.html . Accessed 24 Feb 2017.